Credit: Getty Images Investigators explore the biomarker potential of circulating tumor DNA and tumor suppressor gene status. Elevated circulating tumor DNA fraction and tumor suppressor gene loss are ...

—This recent analysis found that, despite similar clinical outcomes, genomic differences were observed in mCRPC differences by race, highlighting the importance of racial diversity in future genomic ...

A sensitivity analysis in the UK Biobank (UKB) excluded individuals taking medications that could affect PSA (that is, 5-alpha reductase inhibitors and testosterone). For PSA-associated variants, our ...

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests - Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris - can help doctors make better decisions ...

SALT LAKE CITY, May 26, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test ...

Intensification of androgen deprivation therapy (ADT) in metastatic hormone sensitive prostate cancer (mHSPC): Patterns of use and impact on outcomes from a large academic medical center. Evaluating ...

Among men worldwide, prostate cancer is the second most common cancer and the fifth leading cause of cancer deaths. As the world's population ages, the number of prostate cancer patients is expected ...

It is not unusual for advanced prostate cancer to become resistant to treatment. Of these resistant cases, some progress to a specific form of the disease, which is particularly aggressive and deadly.

In the largest clinical genomic profiling study of non-Hispanic Black men with metastatic prostate cancer to date, researchers from Moffitt Cancer Center, University of Pennsylvania, University of ...

Prostate cancer disproportionately affects men of African ancestry, yet the molecular mechanisms underlying these disparities remain poorly defined. Genomic studies have begun to reveal ...

Prostate Screening EpiSwitch (PSE) blood test shows significant potential as an accurate and rapid cancer screening diagnostic High accuracy (94%), PPV (92%), and NPV (94%) reported in the high-impact ...